future periods. These may often be identified by the use of words such as will, may, could, should, would, project,
believe, anticipate, expect, plan, estimate, forecast, potential, pipeline, intend, continue, target,
seek, and variations of these words or comparable words. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking
statements. Factors that could cause or contribute to such differences include, but are not limited to: with respect to the Combination, the parties ability to meet expectations regarding the timing, completion and accounting and tax
treatments of the Combination, changes in relevant tax and other laws, the parties ability to consummate the Combination, the conditions to the completion of the Combination, including receipt of approval of Mylans shareholders, not
being satisfied or waived on the anticipated timeframe or at all, the regulatory approvals required for the Combination not being obtained on the terms expected or on the anticipated schedule or at all, the integration of Mylan and the Upjohn
Business being more difficult, time consuming or costly than expected, Mylans and the Upjohn Businesss failure to achieve expected or targeted future financial and operating performance and results, the possibility that the combined
company may be unable to achieve expected benefits, synergies and operating efficiencies in connection with the Combination within the expected time frames or at all or to successfully integrate Mylan and the Upjohn Business, customer loss and
business disruption being greater than expected following the Combination, the retention of key employees being more difficult following the Combination, changes in third-party relationships and changes in the economic and financial conditions of
the business of Mylan or the Upjohn Business; actions and decisions of healthcare and pharmaceutical regulators; failure to achieve expected or targeted future financial and operating performance and results; uncertainties regarding future demand,
pricing and reimbursement for our or the Upjohn Businesss products; any regulatory, legal or other impediments to Mylans or the Upjohn Businesss ability to bring new products to market, including, but not limited to, where Mylan or
the Upjohn Business uses its business judgment and decides to manufacture, market and/or sell products, directly or through third parties, notwithstanding the fact that allegations of patent infringement(s) have not been finally resolved by the
courts (i.e., an at-risk launch); success of clinical trials and Mylans or the Upjohn Businesss ability to execute on new product opportunities; any changes in or difficulties with our
or the Upjohn Businesss manufacturing facilities, including with respect to remediation and restructuring activities, supply chain or inventory or the ability to meet anticipated demand; the scope, timing and outcome of any ongoing legal
proceedings, including government investigations, and the impact of any such proceedings on our or the Upjohn Businesss financial condition, results of operations and/or cash flows; the ability to meet expectations regarding the accounting and
tax treatments of acquisitions, including Mylans acquisition of Mylan Inc. and Abbott Laboratories non-U.S. developed markets specialty and branded generics business; changes in relevant tax and
other laws, including but not limited to changes in the U.S. tax code and healthcare and pharmaceutical laws and regulations in the U.S. and abroad; any significant breach of data security or data privacy or disruptions to our or the Upjohn
Businesss information technology systems; the ability to protect intellectual property and preserve intellectual property rights; the effect of any changes in customer and supplier relationships and customer purchasing patterns; the ability to
attract and retain key personnel; the impact of competition; identifying, acquiring, and integrating complementary or strategic acquisitions of other companies, products, or assets being more difficult, time-consuming or costly than anticipated; the
possibility that Mylan may be unable to achieve expected synergies and operating efficiencies in connection with strategic acquisitions, strategic initiatives or restructuring programs within the expected time-frames or at all; uncertainties and
matters beyond the control of management, including but not limited to general political and economic conditions and global exchange rates; and inherent uncertainties involved in the estimates and judgments used in the preparation of financial
statements, and the providing of estimates of financial measures, in accordance with U.S. GAAP and related standards or on an adjusted basis. For more detailed information on the risks and uncertainties associated with Mylans business
activities, see the risks described in Mylans Annual Report on Form 10-K for the year ended December 31, 2018, as amended, Mylans Quarterly Report on Form
10-Q for the quarter ended June 30, 2019 and our other filings with the Securities and Exchange Commission (the SEC). These risks, as well as other risks associated with Mylan, the Upjohn
Business, the combined company and the Combination are also more fully discussed in the registration statement on Form S-4 which includes a proxy statement/prospectus (the Form S-4), and Form 10 which includes an information statement (the Form 10), each of which has been filed by Upjohn Inc. (Newco) with the SEC on October 25, 2019 (and has not yet been
declared effective) in connection with the Combination. You can access Pfizers, Newcos and Mylans filings with the SEC through the SEC website at www.sec.gov or through Pfizers or our website, and Mylan strongly encourages
you to do so. Mylan routinely posts information that may be important to investors on our website at investor.mylan.com, and we use this website address as a means of disclosing material information to the public in a broad, non-exclusionary manner for purposes of the SECs Regulation Fair Disclosure (Reg FD). The contents of our website are not incorporated into this release. Pfizer, Newco and Mylan undertake no obligation to
update any statements herein for revisions or changes after the date of this release other than as required by law.
10